0
Abstract: Poster Presentations |

A Randomized, Double-Blind, Placebo-Controlled, Single-Center Pilot Study to Determine the Efficacy of Recombinant Human Interleukin IL-11 (Neumega) in Treating Thrombocytopenia in Burn Patients FREE TO VIEW

Bruce Friedman, MD; Joseph R. Shaver, M.D; William Hickerson, MD; Joan Wilson, RN, BSN; Joseph M. Still, MD
Author and Funding Information

Private, Doctors Hospital Augusta, Augusta, GA


Chest


Chest. 2003;124(4_MeetingAbstracts):181S. doi:10.1378/chest.124.4_MeetingAbstracts.181S
Text Size: A A A
Published online

Abstract

PURPOSE:  Thrombocytopenia is a common complication of acute burn injury. It results from dilutional and other multi-factorial processes. IL-11 stimulates mega-karyocytopoiesis. We hypothesized using IL-11 in burns would reverse thrombocytopenia and decrease blood products usage.

METHODS:  25 patients were randomized to receive placebo or 50mcg/kg SC IL-11 if the platelet count decreased by a predetermined schema. Baseline demographics, serial lab data, adverse events and transfusion requirements were analysed over 14 days.

RESULTS:  Placebo (12), IL-11 (13) patients were statistically matched for age, gender, and TBSA (median 35% for both groups). Mean and median platelets versus time by treatment groups was not statistically different (0.756). A positive trend to reduction of platelet transfusions was shown by Wilcoxon and Bootstrap analysis (p-0.431). No differences were detected in RBC transfusions. Kaplan-Meier analysis on time to effect was also inconclusive. Adverse events were documented but no differences were detected between groups.CONCLUSIONS: IL-11 stimulates mega-keryocyte function and platelet restoration. However, when compared to placebo in acute burns the null hypothesis is not proven. A trend in platelet transfusion needs was noted in the IL-11 group. Our sample size may not have been powered to detect our clinical and scientific observations.

CLINICAL IMPLICATIONS:  Neumega (IL-11) may still be an important adjunctive therapy in the critically ill. A large multicenter trial is warranted.

DISCLOSURE:  B. Friedman, Wyeth-Ayerst Pharmaceuticals, grant monies, discussion of product research or unlabeled uses of product.

Wednesday, October 29, 2003

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543